What Analysts Are Saying About AnaptysBio Stock
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of ratings for AnaptysBio (NASDAQ:ANAB) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 20.96% to $54.43. AnaptysBio is a clinical-stage biotech company with significant revenue growth but challenges in ROE and ROA.
September 26, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio has received mixed analyst ratings, with a recent increase in the average price target to $54.43, indicating positive sentiment. The company shows strong revenue growth but faces challenges in ROE and ROA.
The increase in the average price target by 20.96% suggests positive sentiment among analysts, which could lead to a short-term price increase. However, the company's challenges in ROE and ROA may temper long-term expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100